Janux Therapeutics Series A

Janux Therapeutics is a clinical-stage biopharmaceutical company developing precision-engineered immunotherapies. Their proprietary TRACTr, TRACIr, and ARM platforms are designed to selectively modulate T cells to fight cancer and autoimmune diseases, aiming to transform patients' lives. They are currently evaluating their lead tumor-activated T cell engager (TRACTr) in a clinical trial for prostate cancer.